SG11201808152PA - Dna antibody constructs and method of using same - Google Patents

Dna antibody constructs and method of using same

Info

Publication number
SG11201808152PA
SG11201808152PA SG11201808152PA SG11201808152PA SG11201808152PA SG 11201808152P A SG11201808152P A SG 11201808152PA SG 11201808152P A SG11201808152P A SG 11201808152PA SG 11201808152P A SG11201808152P A SG 11201808152PA SG 11201808152P A SG11201808152P A SG 11201808152PA
Authority
SG
Singapore
Prior art keywords
international
november
september
pct
lane
Prior art date
Application number
SG11201808152PA
Inventor
David Weiner
Karuppiah Muthumani
Seleeke Flingai
Niranjan Sardesai
Sarah Elliott
Jian Yan
Ami Patel
Original Assignee
David Weiner
Karuppiah Muthumani
Seleeke Flingai
Niranjan Sardesai
Sarah Elliott
Jian Yan
Ami Patel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai, Sarah Elliott, Jian Yan, Ami Patel filed Critical David Weiner
Publication of SG11201808152PA publication Critical patent/SG11201808152PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION ,11,,,„,,,,,, ,,,„,1111111111111111111111111111 111111 1111111111111111111111111111111111111 (19) World Intellectual Property Organization International Bureau --, (10) International Publication Number (43) International Publication Date ...../ WO 2017/165460 A9 28 September 2017 (28.09.2017) WIP0 I PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 39/00 (2006.01) Cl 2N 9/64 (2006.01) kind of regional protection available): ARIPO (BW, GH, C12N 9/48 (2006.01) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (21) International Application Number: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, PCT/US2017/023479 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (22) International Filing Date: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 21 March 2017 (21.03.2017) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English (26) Publication Language: English Published: (30) — with Priority Data: — with 62/311,316 21 March 2016 (21.03.2016) US international search report (Art. 21(3)) sequence listing part of description (Rule 5.2(a)) 62/332,381 05 May 2016 (05.05.2016) US (48) Date of publication of this corrected version: 62/376,162 17 August 2016 (17.08.2016) US 09 November 2017 (09.11.2017) 62/396,748 19 September 2016 (19.09.2016) US (15) Information about Correction: — 62/396,750 19 September 2016 (19.09.2016) US see Notice of 09 November 2017 (09.11.2017) 62/417,093 03 November 2016 (03.11.2016) US 62/429,454 02 December 2016 (02.12.2016) US = 62/429,473 02 December 2016 (02.12.2016) US Inventors; and (72) — Applicants: WEINER, David, B. [US/US]; 717 Beacom (71) Lane, Merion, PA 19066 (US). MUTHUMANI, Karup- = piah [US/US]; 52 Ivy Lane, Cherry Hill, NJ 08002 (US). FLINGAI, Seleeke [US/US]; 1623 Penn Avenue North, = Minneapolis, MN 55411 (US). SARDESAI, Niranjan _ = 480 Mallard Circle, Blue Bell, PA 19422 (US). = [US/US]; ELLIOTT, Sarah [US/US]; P.O. Box 301, Pullman, WA 99163 (US). YAN, Jian [US/US]; 503 Sheffield Drive, = Wallingford, PA 19086 (US). PATEL, Ami [US/US]; 1 = Rainey Court, Philadelphia, PA 19103 (US). = (74) Agent: SLAUGHTER, Alison P. et al.; Riverside Law, = LLP, Glenhardie Corporate Center, 1285 Drummers Lane, = Suite 202, Wayne, PA 19087 (US). Designated States (unless otherwise indicated, for every (81) = kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, _ 0\ PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 71' TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. kr) Il (54) Title: DNA ANTIBODY CONSTRUCTS AND METHOD OF USING SAME C 1-1 (57) : Disclosed herein is a composition comprising the combination of a nucleic acid sequence encoding a desired polypeptide N that elicits an immune response in a mammal and a nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof.
SG11201808152PA 2016-03-21 2017-03-21 Dna antibody constructs and method of using same SG11201808152PA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662311316P 2016-03-21 2016-03-21
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17
US201662396750P 2016-09-19 2016-09-19
US201662396748P 2016-09-19 2016-09-19
US201662417093P 2016-11-03 2016-11-03
US201662429454P 2016-12-02 2016-12-02
US201662429473P 2016-12-02 2016-12-02
PCT/US2017/023479 WO2017165460A1 (en) 2016-03-21 2017-03-29 Dna antibody constructs and method of using same

Publications (1)

Publication Number Publication Date
SG11201808152PA true SG11201808152PA (en) 2018-10-30

Family

ID=59900715

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202009182RA SG10202009182RA (en) 2016-03-21 2017-03-21 Dna antibody constructs and method of using same
SG11201808152PA SG11201808152PA (en) 2016-03-21 2017-03-21 Dna antibody constructs and method of using same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202009182RA SG10202009182RA (en) 2016-03-21 2017-03-21 Dna antibody constructs and method of using same

Country Status (11)

Country Link
US (1) US20190091322A1 (en)
EP (1) EP3432918A4 (en)
JP (2) JP2019509350A (en)
KR (2) KR20230012070A (en)
CN (1) CN109890407A (en)
AU (1) AU2017238168A1 (en)
BR (1) BR112018069297A2 (en)
CA (1) CA3018566A1 (en)
MX (1) MX2018011425A (en)
SG (2) SG10202009182RA (en)
WO (1) WO2017165460A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516075A (en) * 2013-03-15 2016-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Synthetic immunogens for the prevention or treatment of tuberculosis
SG11201809783RA (en) * 2016-05-05 2018-12-28 Univ Pennsylvania Dna monoclonal antibodies targeting influenza virus
CA3035932A1 (en) * 2016-09-14 2018-03-22 Abbvie Biotherapeutics Inc. Anti-pd-1 antibodies and their uses
CA3037486A1 (en) * 2016-09-19 2018-03-22 The Trustees Of The University Of Pennsylvania Combination of novel vaccines against zika virus and dna antibody constructs for use against zika virus
KR20230111264A (en) * 2016-11-07 2023-07-25 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 Dna antibody constructs for use against lyme disease
KR20190114963A (en) * 2016-12-02 2019-10-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 DNA Antibody Constructs for Use Against Ebola Virus
US20200216519A1 (en) * 2017-09-15 2020-07-09 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against ebola virus
WO2019075300A2 (en) * 2017-10-12 2019-04-18 The Wistar Institute Of Anatomy And Biology Mayaro virus consensus antigens, dna antibody constructs for use against mayaro virus, and combinations thereof
US20210047388A1 (en) * 2018-01-31 2021-02-18 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against ebola virus
WO2019152603A1 (en) * 2018-01-31 2019-08-08 The Wistar Institute Of Anatomy And Biology Nucleic acid antibody constructs for use against zika virus
US20200362055A1 (en) * 2018-01-31 2020-11-19 The Wistar Institute Of Anatomy And Biology Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use
US20220298211A1 (en) * 2019-06-04 2022-09-22 Qiang Chen PLANT-PRODUCED mABs AGAINST CHIKUNGUNYA VIRUS WITH ENHANCED EFFECTOR FUNCTION AND EFFICACY
US20230203133A1 (en) * 2020-05-07 2023-06-29 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against hepatitis b virus
US20230341408A1 (en) * 2020-06-08 2023-10-26 University Of Florida Research Foundation, Inc. Materials and methods for the diagnosis and treatment of cancer
WO2023183818A2 (en) * 2022-03-21 2023-09-28 University Of Georgia Research Foundation, Inc. A novel h1n1 antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606425D0 (en) * 1996-03-27 1996-06-05 Binding Site Ltd Improvements in and relating to the production of antibodies and test kits incorporating antibodies
CN1480215A (en) * 2003-07-07 2004-03-10 叶新新 Compound antibody vaccine of SARS virus antigen as well as its model of experimental animal and method
JP5744719B2 (en) * 2008-04-04 2015-07-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Chikungunya virus protein consensus sequence, nucleic acid molecule encoding the same, and compositions and methods using the same
US20110045534A1 (en) * 2009-08-20 2011-02-24 Cell Signaling Technology, Inc. Nucleic Acid Cassette For Producing Recombinant Antibodies
EP3909973A3 (en) * 2010-11-12 2022-01-26 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
US9994629B2 (en) * 2012-12-13 2018-06-12 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a synthetic antibody
SG11201604719WA (en) * 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same

Also Published As

Publication number Publication date
JP2022121440A (en) 2022-08-19
AU2017238168A1 (en) 2018-10-18
CN109890407A (en) 2019-06-14
MX2018011425A (en) 2019-09-04
BR112018069297A2 (en) 2019-01-22
WO2017165460A9 (en) 2017-11-09
JP2019509350A (en) 2019-04-04
US20190091322A1 (en) 2019-03-28
KR20230012070A (en) 2023-01-25
EP3432918A1 (en) 2019-01-30
WO2017165460A1 (en) 2017-09-28
KR20180138204A (en) 2018-12-28
CA3018566A1 (en) 2017-09-28
EP3432918A4 (en) 2020-02-12
SG10202009182RA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
SG11201808152PA (en) Dna antibody constructs and method of using same
SG11201809789SA (en) Dna monoclonal antibodies targeting checkpoint molecules
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201906468TA (en) Chimeric antigen receptors against axl or ror2 and methods of use thereof
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201909395TA (en) Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
SG11201900138TA (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201807286WA (en) Methods and compositions for transducing lymphocytes and regulated expansion thereof
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201806639VA (en) New streptococcal proteases
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201901684XA (en) Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201809620UA (en) The contorsbody - a single chain target binder
SG11201804721SA (en) Modulators of complement activity